Fungal Ergosterol Synthesis Inhibition Module

The fungal ergosterol biosynthesis pathway and the points at which the most widely used antifungal classes interrupt it, structured as a causal enzymatic cascade. Ergosterol is the fungal-specific membrane sterol, the functional analogue of cholesterol in mammalian cells; it maintains membrane fluidity, integrity, and the function of membrane-embedded proteins, and its biosynthesis is the most exploited antifungal target because the pathway is essential and fungal-specific. This module traces the pathway as successive biological steps: squalene is first epoxidised by squalene epoxidase (Erg1) — an early committed step and the target of the allylamines terbinafine and naftifine; the pathway then proceeds to lanosterol 14-alpha-demethylation by the cytochrome P450 Cyp51 (Erg11) — the target of the azoles (the triazoles fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, and the topical imidazoles such as clotrimazole and miconazole), the antifungal workhorse class; ergosterol is then produced and incorporated into the fungal plasma membrane. Blocking either enzyme depletes ergosterol and causes accumulation of squalene or toxic methylated sterol intermediates, producing membrane dysfunction, growth inhibition, and (for terbinafine) fungicidal cell death — the antifungal consequence onto which both enzyme blocks converge. The module also encodes why azole therapy is failure-prone — point mutations in and overexpression of CYP51/ERG11, drug-efflux pumps (CDR/MDR), and the environmental Aspergillus fumigatus TR34/L98H allele select for azole resistance off the demethylase target. This module defines the mechanism-of-action design pattern for ergosterol-synthesis-targeting antifungal treatments: conforming fungal-disease entries link a treatment to the specific enzymatic step it inhibits via target_mechanisms.